C225

C225

A chimeric IgG antibody with a strong binding affinity for epidermal growth factor (EGF) receptor, which blocks ligand—EGF, TGF α, etc.—binding and inhibits cell proliferation. C225 made it through to Phase III trials, during which time it was renamed cetuximab (Erbitux), and has proved to be a blockbuster cancer drug for head and neck cancer, colorectal and other cancers.